Metupuk Are Delighted by the Scottish Medicines Consortium (SMC) Acceptance of Enhertu (Trastuzumab Deruxtecan) for Routine Use on the NHS

The SMC has accepted Trastuzumab deruxtecan (Enhertu) for treating HER2-positive unresectable or metastatic breast cancer in adults who have received one or more prior anti-HER2 based therapies for routine use on the NHS in Scotland.